Status:
TERMINATED
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity. ...
Eligibility Criteria
Inclusion
- Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent
- Body mass index (BMI) between 27.0 and 34.9 kg/m\^2 (both inclusive)
- Body weight between 70.0 and 130.0 kg (both inclusive)
Exclusion
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method
- Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
- Inability or unwillingness to perform self-injection
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2019
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04012255
Start Date
July 15 2019
End Date
October 22 2019
Last Update
October 23 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mainz, Germany, 55116
2
Novo Nordisk Investigational Site
Neuss, Germany, 41460